Is this "healthy" drink in your fridge? ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎
‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎ ‎




No longer interested? Unsubscribe
<[link removed]>



<[link removed]>



THE BREAKFAST DRINK BEHIND RECURRING UTIS [VIDEO]



 

 






Could your "healthy" morning drink be why your UTIs keep coming back?

Dr. Evelyn Hart says YES...

She watched it happen to her own mother.

<[link removed]>
See what Dr. Hart found in her mother's fridge
<[link removed]>

To your health!


If you'd rather not receive these emails, you can unsubscribe here
<[link removed]>
.
 


In a Randomized Trial, Glucose Monitors Lowered A1C for Type 2 Diabetes
Without Insulin The NEJM-published CONNECT trial found adults using continuous
glucose monitors lowered A1C 0.9 point more than those using fingerstick tests
over 26 weeks.




The Capital Brief October 15
Diabetes Care Edition
In a Randomized Trial, Glucose Monitors Lowered A1C for Type 2 Diabetes
Without Insulin


Continuous glucose monitors are standard for many people who use insulin.
Whether they help people with type 2 diabetes who do not use insulin has been
less clear. A randomized trial now offers stronger evidence. The CONNECT trial
was published in the New England Journal of Medicine on October 14, led by
researchers at the University of Colorado Anschutz and the Jaeb Center for
Health Research. It enrolled 283 adults with type 2 diabetes not treated with
insulin at 22 primary care practices in the United States, and followed them
for 26 weeks. Participants were randomly assigned to use a Dexcom G7 continuous
glucose monitor or to continue routine care with fingerstick blood glucose
testing. Both groups received diet and exercise education and stayed on their
usual medications. According to the investigators and sponsor, A1C fell 1.6
points in the monitor group from an average of 8.8%, 0.9 point more than with
routine care. Time spent in the target glucose range was about 62% with
monitors versus 41% with routine care, roughly five more hours a day. This was
a randomized trial, but it was relatively small, lasted six months and was
sponsored by the device maker. Results were first presented in June and now
appear as a peer-reviewed paper. The useful idea is that real-time feedback may
help people see how daily choices affect blood sugar. This edition explores the
evidence, not a device recommendation. Diabetes management decisions belong
with a clinician.

01 What the trial tested
A continuous glucose monitor uses a small sensor under the skin to measure
glucose every few minutes. Readings are sent to a phone or receiver, showing
trends and responses to meals and activity. Most people with type 2 diabetes do
not use insulin and manage with oral or injectable medications. For them,
fingerstick testing is often infrequent or not recommended. Insurance coverage
for monitors in this group has been limited. An earlier observational study,
covered in this newsletter, linked sustained monitor use to better outcomes in
high-risk type 2 diabetes. CONNECT tested the question with a randomized design.

02 How the trial was designed
The trial enrolled 283 adults at 22 primary care practices. Participants had
an average age of about 60, and about a third were from racial or ethnic
minority groups. Average starting A1C was 8.8%, and about 31% had A1C of 9% or
higher. About 40% were taking GLP-1-based medications and about 37% SGLT2
inhibitors. Participants were randomly assigned to a monitor or routine care
with a fingerstick meter. The main outcome was change in A1C after 26 weeks.
265 participants completed the trial.

03 What was found
A1C fell 1.6 points in the monitor group, 0.9 point more than in the routine
care group, according to the investigators and sponsor. Time in the target
range of 70 to 180 mg/dL was about 62% with monitors and 41% with routine care.
The difference appeared within the first weeks and lasted through 26 weeks.
About 68% of monitor users reached an A1C below 7.5%, and 46% below 7.0%,
according to the sponsor. Monitor users reported greater satisfaction with
glucose monitoring and less diabetes distress. Participants wore the sensor
most of the time throughout the study. Confidence intervals and full safety
data are reported in the published paper.

04 Who benefited
According to conference coverage, people with starting A1C above 10% saw
especially large reductions. Benefits were also reported among people taking
GLP-1 drugs and SGLT2 inhibitors. People taking no diabetes medications also
improved. The sponsor said benefits were consistent across age, sex, race and
ethnicity, income and education. Subgroup results in small trials should be
interpreted cautiously. Primary care settings make the findings relevant to
where most diabetes care happens. Real-world results may differ from trial
conditions.

05 Why monitors might help
Seeing glucose rise after a meal can prompt changes in food choices or
portions. Real-time data can show the effects of walking after meals.
Clinicians can use monitor data to adjust treatment more precisely. Feedback
may increase motivation and engagement. Monitors can also detect patterns that
fingerstick tests miss. The trial did not isolate which of these factors
mattered most. Benefits depend on people using the information.

06 Study limits
The trial was relatively small, with 283 participants. It lasted 26 weeks; a
12-month extension is underway. It tested one device brand and was sponsored by
its maker, Dexcom. Participants and clinicians knew who was using a monitor.
The figures here come from investigator and sponsor reports; details should be
checked in the published paper. The trial measured A1C and glucose patterns,
not long-term complications. Cost and insurance coverage were not addressed.

07 What people with diabetes can do
Ask your clinician whether a continuous glucose monitor could help your
diabetes management. Check insurance coverage, which varies by plan and
treatment. Over-the-counter monitors are available, but discuss how to
interpret data with a clinician. Use readings to learn how meals, activity and
sleep affect your glucose. Share data with your care team at visits. Continue
taking prescribed medications unless your clinician advises a change. A monitor
is a tool, not a substitute for overall care.

08 The long view on diabetes technology
Diabetes tools are becoming more accessible to people beyond those using
insulin. This trial suggests monitors can meaningfully lower A1C for people
with type 2 diabetes not on insulin. For individuals, practical questions
include: Would real-time data change my habits? Is a monitor covered? How will
I use the information? For health systems and insurers, the findings may inform
coverage decisions. For researchers, longer and independent studies would
strengthen the evidence. The long-view idea is that visible feedback can make
invisible changes concrete. What you can see, you can manage.


The Takeaway

1 In the CONNECT randomized trial of 283 adults with type 2 diabetes not on
insulin, continuous glucose monitors lowered A1C 0.9 point more than routine
care over 26 weeks.
2 Time in target range was about 62% with monitors versus 41% with routine
care.
3 Participants reported higher satisfaction and less diabetes distress.
4 The trial was small, short and sponsored by the device maker.
5 The findings support considering monitors with a clinician, not a guarantee
of results.
Stay patient, stay curious,
T.C. Brown
Editor, True Capital Talk


Sources & Further Reading

• Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes — New
England Journal of Medicine, October 14, 2026
<[link removed]>
• Continuous glucose monitoring — National Institute of Diabetes and Digestive
and Kidney Diseases
<[link removed]>
• Diabetes basics — Centers for Disease Control and Prevention
<[link removed]>
• Type 2 diabetes — MedlinePlus, National Library of Medicine
<[link removed]>
For educational and informational purposes only. Nothing here is a diagnosis,
device recommendation, or individualized medical advice. Talk to a qualified
clinician about diabetes management.  


<[link removed]>




TERMS <[link removed]> • PRIVACY
<[link removed]> • UNSUBSCRIBE
<[link removed]>



This message was delivered by True Capital Talk (TCT), a brand of TerraTrance
Technologies, LLC.

Need assistance or have a question? Simply reply to this email or reach us at
[email protected] <mailto:[email protected]>

All content in this email, including text and images, is the property of
TerraTrance Technologies, LLC and may not be copied, redistributed, or shared
without prior written permission.

© 2026 True Capital Talk (TCT). All Rights Reserved.

200 Broadway Blvd NE, Albuquerque, NM 87102

You may unsubscribe
<[link removed]>
at any time if these emails are no longer useful to you.